Chemistry Reference
In-Depth Information
[200] Baringhaus KH, Hessler G. Fast similarity searching and screening hit analysis. Drug
Discovery Today, Technol 2004, 1:197-204.
[201] Maass P, Schulz-Gasch T, Stahl M, Rarey M. Recore: A fast and versatile method for
scaffold hopping based on small molecule crystal structure conformations. J Chem Inf
Model 2007, 47:390-399.
[202] Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P.
Voyages to the (un)known: Adaptive design of bioactive compounds. Trends Biotechnol
2009, 27:18-26.
[203] Hajduk PJ, Greer J. A decade of fragment-based drug design: Strategic advances and
lessons learned. Nat Rev Drug Discov. 2007, 6:211-219.
[204] Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for
proteins: SAR by NMR. Science 1996, 274:1531-1534.
[205] Chessari G, Woodhead AJ. From fragment to clinical candidate—A historical perspective.
Drug Discov Today 2009, 14:668-675.
[206] Schuffenhauer A, Ruedisser S,Marzinzik AL, JahnkeW, Blommers M, Selzer P, Jacoby E.
Library design for fragment based screening. Curr Top Med Chem 2005, 5:751-762.
[207] Siegal G, Ab E, Schultz J. Integration of fragment screening and library design. Drug
Discov Today 2007, 12:1032-1039.
[208] Lepre CA, Moore JM, Peng JW. Theory and applications of NMR-based screening in
pharmaceutical research. Chem Rev 2004, 104:3641-3676.
[209] Swayze EE, Jefferson EA, Sannes-Lowery KA, Blyn LB, Risen LM, Arakawa S, Osgood
SA, Hofstadler SA, Griffey RH. SAR byMS: A ligand based technique for drug lead
discovery against structured RNA targets. J Med Chem 2002, 45:3816-3819.
[210] Erlanson DA,Wells JA, Braisted AC. Tethering:Fragment-based drug discovery. AnnuRev
Biophys Biomol Struct 2004, 33:199-223.
[211] Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-
based lead discovery using X-ray crystallography. J Med Chem 2005, 48:403-413.
[212] Danielson UH. Fragment library screening and lead characterization using SPR biosensors.
Curr Top Med Chem 2009, 9:1725-1735.
[213] Neumann T, Junker HD, Schmidt K, Sekul R. SPR-based fragment screening: Advantages
and applications. Curr Top Med Chem 2007, 7:1630-1642.
[214] Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev Drug
Discov 2004, 3:660-672.
[215] Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011,10:811-
812.
[216] Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem 2009, 1:187-
192.
[217] Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based
drug discovery. J Med Chem 2008,51:3661-3680.
[218] Zartler ER, Shapiro MJ. Fragonomics: Fragment-based drug discovery. Curr Opin Chem
Biol 2005, 9:366-370.
[219] Bembenek SD, Tounge BA, Reynolds CH. Ligand efficiency and fragment-based drug
discovery. Drug Discov Today 2009, 14:278-283.
[220] Fruh V, Zhou Y, Chen D, Loch C, Ab E, Grinkova YN, Verheij H, Sligar SG, Bushweller
JH, Siegal G. Application of fragment-based drug discovery to membrane proteins:
